Methods and Results
Among 1809 patients who underwent PCI and received stent placement (FU-registry), we selected 774 DM patients, then divided them into 2 groups: a poor-glycemic-control group, who showed greater than 6.9% HbA1c at the time of PCI (Pre-HbA1c) (“≥ 6.9 group”, n = 357) and a good-glycemic-control group, who showed less than < 6.9% at Pre-HbA1c (“< 6.9 group”, n = 417). The patients in the ≥ 6.9 group were further divided into two groups for further comparisons: a “DM control group” and a “Poor control group”. At follow-up (300 days), there was no difference in major adverse cardiac event (MACE) between the < 6.9 group and ≥ 6.9 groups, as well as between the DM control group and Poor control group. In a multivariate analysis, there was no relationship between the incidence of MACE and Pre-HbA1c, Pre- HbA1c ≥ 6.9% or the HbA1c difference (Pre-HbA1c − HbA1c at follow-up), however, patients treated with insulin (OR:2.23, 95% CI: 1.50–3.30) or thiazolidine (OR:1.9, 95% CI: 1.07–3.41) positively related to MACE, while biguanide (OR:0.17, 95% CI: 0.03–0.59) negatively related to MACE. Insulin treated DM patients with HbA1c < 6.5% tended to have increased MACE ( Fig. 1 ).
